Imara attempts to spin weak data into an 'encouraging' result — but investors aren't having it
Imara unveiled data from two subgroups of a Phase IIa trial for its lead compound Wednesday, aiming to conjure up a positive light despite challenges tied to the Covid-19 pandemic. But investors weren’t buying it and sent the company’s shares into a tailspin.
The experimental drug, dubbed IMR-687, is being evaluated for sickle cell disease as both a monotherapy and in combination with hydroxyurea. In the monotherapy subgroup, Imara reported IMR-687 showed no meaningful changes in F-cells, fetal hemoglobin (HbF) levels or Hb levels from baseline after 24 weeks.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.